CF
PCRX icon

Centaurus Financial’s Pacira BioSciences PCRX Stock Holding History

Centaurus Financial’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,055
Closed -$98K – 1594
2018
Q2 		$98K Buy
+3,055
New +$105K 0.01% 719

Other funds holding PCRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Centaurus Financial's PCRX Position: Q3 2018 in Review

Centaurus Financial sold out of Pacira BioSciences (PCRX) in Q3 2018, closing a stake of 3,055 shares — an estimated $98K sold.

Centaurus Financial first reported a position in PCRX in Q2 2018 and held it in 1 quarter. The position peaked at $98K in Q2 2018. 187 funds tracked by Wall St. Rank hold PCRX as of Q3 2018.

  • Centaurus Financial reported no remaining Pacira BioSciences position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 3,055 Pacira BioSciences shares in Q3 2018, an estimated $98K.
  • Centaurus Financial first reported a position in Pacira BioSciences in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Pacira BioSciences position peaked at $98K in Q2 2018.
  • 187 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.